 NEW YORK and MIAMI, Sept. 24, 2021 GLOBE NEWSWIRE -- Pfizer Inc. NYSE: PFE and OPKO Health Inc. NASDAQ: OPK announced today that the U.S. Food and Drug Administration FDA has extended the review period for the Biologics License Application BLA for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency GHD in pediatric patients. The Prescription Drug User Fee Act PDUFA goal date has been extended by three months to January 2022, as a result of Pfizers submission of additional data to the original BLA. 